S&P 500   5,015.60 (+0.09%)
DOW   37,961.30 (+0.49%)
QQQ   420.93 (-0.59%)
AAPL   165.98 (-0.63%)
MSFT   403.65 (-0.15%)
META   494.29 (-1.50%)
GOOGL   154.50 (-0.97%)
AMZN   177.59 (-0.91%)
TSLA   148.60 (-0.89%)
NVDA   837.10 (-1.13%)
AMD   151.34 (-2.41%)
NIO   3.86 (-3.50%)
BABA   68.58 (-0.44%)
T   16.34 (+0.06%)
F   12.15 (+0.75%)
MU   109.95 (-1.77%)
GE   152.24 (-0.46%)
CGC   7.89 (+0.77%)
DIS   111.98 (-0.40%)
AMC   2.85 (-2.40%)
PFE   25.43 (+0.16%)
PYPL   62.14 (+0.06%)
XOM   119.73 (+1.02%)
S&P 500   5,015.60 (+0.09%)
DOW   37,961.30 (+0.49%)
QQQ   420.93 (-0.59%)
AAPL   165.98 (-0.63%)
MSFT   403.65 (-0.15%)
META   494.29 (-1.50%)
GOOGL   154.50 (-0.97%)
AMZN   177.59 (-0.91%)
TSLA   148.60 (-0.89%)
NVDA   837.10 (-1.13%)
AMD   151.34 (-2.41%)
NIO   3.86 (-3.50%)
BABA   68.58 (-0.44%)
T   16.34 (+0.06%)
F   12.15 (+0.75%)
MU   109.95 (-1.77%)
GE   152.24 (-0.46%)
CGC   7.89 (+0.77%)
DIS   111.98 (-0.40%)
AMC   2.85 (-2.40%)
PFE   25.43 (+0.16%)
PYPL   62.14 (+0.06%)
XOM   119.73 (+1.02%)
S&P 500   5,015.60 (+0.09%)
DOW   37,961.30 (+0.49%)
QQQ   420.93 (-0.59%)
AAPL   165.98 (-0.63%)
MSFT   403.65 (-0.15%)
META   494.29 (-1.50%)
GOOGL   154.50 (-0.97%)
AMZN   177.59 (-0.91%)
TSLA   148.60 (-0.89%)
NVDA   837.10 (-1.13%)
AMD   151.34 (-2.41%)
NIO   3.86 (-3.50%)
BABA   68.58 (-0.44%)
T   16.34 (+0.06%)
F   12.15 (+0.75%)
MU   109.95 (-1.77%)
GE   152.24 (-0.46%)
CGC   7.89 (+0.77%)
DIS   111.98 (-0.40%)
AMC   2.85 (-2.40%)
PFE   25.43 (+0.16%)
PYPL   62.14 (+0.06%)
XOM   119.73 (+1.02%)
S&P 500   5,015.60 (+0.09%)
DOW   37,961.30 (+0.49%)
QQQ   420.93 (-0.59%)
AAPL   165.98 (-0.63%)
MSFT   403.65 (-0.15%)
META   494.29 (-1.50%)
GOOGL   154.50 (-0.97%)
AMZN   177.59 (-0.91%)
TSLA   148.60 (-0.89%)
NVDA   837.10 (-1.13%)
AMD   151.34 (-2.41%)
NIO   3.86 (-3.50%)
BABA   68.58 (-0.44%)
T   16.34 (+0.06%)
F   12.15 (+0.75%)
MU   109.95 (-1.77%)
GE   152.24 (-0.46%)
CGC   7.89 (+0.77%)
DIS   111.98 (-0.40%)
AMC   2.85 (-2.40%)
PFE   25.43 (+0.16%)
PYPL   62.14 (+0.06%)
XOM   119.73 (+1.02%)
Free Trial
OTCMKTS:OMBP

Omni Bio Pharmaceutical (OMBP) Stock Price, News & Analysis

→ I’m officially sounding the alarm. (From Altimetry) (Ad)
Free OMBP Stock Alerts
$0.0010
0.00 (0.00%)
(As of 08/18/2020)
Compare
Today's Range
$0.0010
▼
$0.0010
50-Day Range
N/A
52-Week Range
$0.00
▼
$0.04
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis

About Omni Bio Pharmaceutical

Omni Bio Pharmaceutical, Inc. operates as a biopharmaceutical company in the United States. It holds a license to use patent for the treatment of diabetes using plasma-derived alpha-1 antitrypsin (p-AAT), a protein that is purified from human blood. The company also holds licenses for the use of patents and patent applications covering the use of p-AAT in the treatment of cellular transplantation and graft rejection, radiation protection, bacterial and viral diseases, myocardial remodeling, and inflammatory bowel disease indications. In addition, it holds licenses for patent applications covering compositions of various Fc-AAT constructs. Omni Bio Pharmaceutical, Inc. was founded in 2006 and is headquartered in Fort Collins, Colorado.

OMBP Stock Price History

OMBP Stock News Headlines

March 2, 2024 | morningstar.com
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Class A
December 2, 2023 | investing.com
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349)
April 19, 2024 | Altimetry (Ad)
I’m officially sounding the alarm.
AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.
November 12, 2023 | morningstar.com
Shanxi Jinbo Bio pharmaceutical Co Ltd 832982
October 6, 2023 | nasdaq.com
Oversold Conditions For BridgeBio Pharma (BBIO)
August 24, 2023 | morningstar.com
Sinopep Allsino Bio Pharmaceutical Co Ltd Class A
May 16, 2023 | wsj.com
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd.
April 22, 2023 | marketwatch.com
2023 Bio Pharma Logistics Market | Dynamic Report By 2030
April 19, 2024 | Altimetry (Ad)
I’m officially sounding the alarm.
AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.
April 21, 2023 | morningstar.com
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Class H
March 31, 2023 | marketwatch.com
Bio-pharma Market Key Players and Forecast till 2031
March 29, 2023 | marketwatch.com
2023 Bio Pharma Logistics Market Size, Growth | Global Industry Trends [2029]
March 25, 2023 | thestreet.com
My Five Favorite Bio-Pharma Stocks from the J.P. Morgan Healthcare Conference
March 22, 2023 | wsj.com
Zhejiang Wolwo Bio Pharmaceutical Co. Ltd.
February 22, 2023 | morningstar.com
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Class A 300357 Stock Quote
January 27, 2023 | marketwatch.com
Bio Pharma Logistics Market [Latest Report ]2023 is Booming with Figures, Sales Volume, Financial Barriers and Outlook to 2027
January 5, 2023 | forbes.com
BioMarin Pharmaceutical
October 7, 2022 | reuters.com
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
September 22, 2022 | investing.com
Sinopep Allsino Bio Pharmaceutical Co Ltd (688076)
July 8, 2022 | apnews.com
Slingshot Biosciences, Inc. Partners with OLS – OMNI Life Science to Distribute Synthetic Cells Throughout Germany, Austria, Switzerland, and Italy
See More Headlines
Receive OMBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omni Bio Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/19/2024
Fiscal Year End
3/31/2025
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
OTCMKTS:OMBP
CUSIP
N/A
CIK
1389870
Web
www.omnibiopharma.com
Phone
970-237-5178
Fax
N/A
Employees
1
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
Investing Strategies To Help Grow Your Retirement Income Cover
Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

OMBP Stock Analysis - Frequently Asked Questions

How have OMBP shares performed in 2024?

Omni Bio Pharmaceutical's stock was trading at $0.0010 at the beginning of the year. Since then, OMBP shares have increased by 0.0% and is now trading at $0.0010.
View the best growth stocks for 2024 here.

What other stocks do shareholders of Omni Bio Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omni Bio Pharmaceutical investors own include Xenon Pharmaceuticals (XENE), aTyr Pharma (LIFE), 23895 (GKX.V) (GKX), Flexion Therapeutics (FLXN), Biocept (BIOC) and Acorda Therapeutics (ACOR).

How do I buy shares of Omni Bio Pharmaceutical?

Shares of OMBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:OMBP) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
Urgent alert: open this for a huge profit potential
Timothy Sykes
How Biden has already won 2024
Porter & Company